#

 *June 2017 Enquiries: Ed Littlewood (+44 1453 524530)*

**Renishaw highlights MDR change at Digital Symposium**

Global engineering and scientific technologies company, [Renishaw](http://www.renishaw.com/en/1030.aspx) is exhibiting at the Digital Symposium at Swansea University on 29th June, 2017 as part of its event, “Digital Futures in Health and Wellbeing: can public services survive without them?” The event will explore how the United Kingdom is preparing businesses and infrastructure for the digital revolution. Renishaw’s Director and General Manager of its Medical and Dental Products Division, Bryan Austin, will also hold a seminar at the event as part of its focus on health services.

Austin’s presentation will focus on the recent update to the European Medical Device Regulation (MDR), which was published in May, 2017. The regulation suggests that any medical device mass produced by means of an industrial process no longer falls under the ‘custom-made’ exemption and therefore requires its own clinical evidence to authorise its sustainability, along with its own CE mark to prove it has been tested and meets all relevant standards.

The problem is that there aren’t clear definitions of ‘mass-produced’ or ‘industrial manufacturing processes’, so there is a risk that some interpretations might include 3D printed patient specific implants when manufactured on an industrial scale, even though each one is unique.

“Despite the European Medical Device Regulation being released, the subsequent guidance documents could be influenced if enough manufacturers have an input,” explained Austin. “Patient specific implants are already being used in surgeries across the world, with Renishaw working specifically with a number of Welsh hospitals to improve patient outcomes. An interpretation of the regulation as it currently stands may mean we will not be able to help patients in the same way. At the Digital Symposium, we hope to raise awareness of the new legislation amongst manufacturers.”

Renishaw will also exhibit its medical implants at the symposium. The company will showcase a recent case study on its work with Cardiff University. For further information on Renishaw visit [www.renishaw.com/](http://www.renishaw.com/).

Ends 321 words

Notes to editors

UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It has over 4,000 employees located in the 35 countries where it has wholly owned subsidiary operations.

For the year ended June 2016 Renishaw recorded sales of £436.6 million of which 95% was due to exports. The company’s largest markets are China, the USA, Japan and Germany.

Throughout its history Renishaw has made a significant commitment to research and development, with historically between 14 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

Renishaw is listed on the London Stock Exchange (LSE:RSW) where it is a constituent of the FTSE 250, with a current valuation of around £1.8 billion.

Further information at [www.renishaw.com](http://www.renishaw.com)